By Adriano Marchese
Neuronetics shares jumped in premarket trading Tuesday after the company said it expects revenue to double from 2024 levels, rising above analyst expectations.
Shares traded 15% higher at $4.89.
For the full-year 2025, the medical device company expects total worldwide revenue to be between $145 million and $155 million. This is up from $74.9 million in 2024, and higher than the $93.5 million forecasted by analysts, according to FactSet.
Gross margins are projected to be 55%, while operating expenses are expected to fall within the range of $90 million to $98 million.
More immediately, in the first quarter, Neuronetics expects total revenue between $28 million and $30 million.
This is up from its latest fourth-quarter results where it generated $22.5 million in revenue, up from $20.3 million, beating analyst projections of a slight decline to $19.6 million and its own guidance range of between $19 million and $20 million.
Net loss in the quarter widened to $12.2 million from $5.4 million, which on a oer-share basis was a loss of 33 cents compared with a loss of 19 cents.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 04, 2025 08:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。